Ras GTPase

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Retrieved on: 
Monday, April 8, 2024
NSCLC, Colorectal cancer, CYPA, RAS, Patient, Research, PDAC, Lung cancer, Protein, Trial of the century, GTP, Cancer, CRC, Pharmacology, Ras GTPase, Drug resistance, Pharmaceutical industry

REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of two peer-reviewed research papers in Nature. The first paper highlights the discovery and preclinical characterization of RMC-7977, a preclinical tool compound representative of a class of oral RAS(ON) multi-selective inhibitors, including the investigational drug candidate RMC-6236, that target multiple RAS variants. The second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC. This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.

Key Points: 
  • The first paper highlights the discovery and preclinical characterization of RMC-7977, a preclinical tool compound representative of a class of oral RAS(ON) multi-selective inhibitors, including the investigational drug candidate RMC-6236, that target multiple RAS variants.
  • The second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC.
  • This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.
  • Oncogenic RAS proteins drive up to 30 percent of all human cancers, most notably non-small cell lung cancer (NSCLC), PDAC and colorectal cancer (CRC).

Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

Retrieved on: 
Wednesday, January 24, 2024
Death, Neoplasm, Patient, Nanoparticle, Therapy, Ras GTPase, RNA, Small RNA, Cancer, NSCLC, Mutation, IND, Lung cancer, FDA, Investigational New Drug, CRC, Clinical trial, Colorectal cancer, Patent, RAS, American Cancer Society

HAMILTON, BERMUDA, Jan. 24, 2024 -- Altamira Therapeutics Ltd. (Nasdaq: CYTO) ("Altamira" or the "Company"), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has filed a second provisional patent application with the United States Patent and Trade Office (USPTO) to provide broad coverage of different KRAS mutations in human cancer treatment with nanoparticles comprising the Company’s OligoPhore™ platform and a single siRNA sequence, polyKRASmut. The nanoparticles are developed by Altamira as AM-401.

Key Points: 
  • The second provisional application contains in vitro data confirming the ability of polyKRASmut siRNA to knock down a broad range of KRAS mutations in cancer cell lines.
  • Since polyKRASmut was tested against only a limited number of mutations, it may potentially knock down other, yet untested mutations.
  • “By combining the polyKRASmut siRNA with our OligoPhore platform we can direct its delivery to the tumor and tackle with one single compound many different KRAS mutations.
  • Only recently, the FDA approved the first two treatments for KRAS-driven cancer: sotorasib and adagrasib, two small molecule inhibitors of G12C-mutated KRAS for the treatment of NSCLC.

Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference

Retrieved on: 
Thursday, March 9, 2023
RAS, KRAS, Ras GTPase, Breast cancer, Breast, HRAS, M.B.A, NRAS, Luminal, Vaccine, Medical imaging, Aquaculture

CARLSBAD, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the presentation of data in two posters at the American Association for Cancer Research (AACR) Special Conference: Targeting RAS. The two posters outlined preclinical studies of the Company’s RAS-targeted program that showed potential anti-RAS activity in both pancreatic and breast cancer models. The conference took place at the Philadelphia Marriott in Philadelphia, Pennsylvania from March 5-8, 2023.

Key Points: 
  • RAS pathways are frequently hyper-activated in breast cancers, and genetic/ epigenetic inactivation of RAS-negative regulators is common.
  • Qualigen’s novel small molecules bound all three main RAS proteins (KRAS, HRAS, and NRAS) and suppressed RAS function.
  • These data demonstrate that Qualigen’s compounds may provide meaningful anti-RAS activity, as a novel approach to breast cancer.
  • RAS is among the most common cancer oncogenes, and RAS-driven tumors represent an area of significant unmet medical need.

Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

Retrieved on: 
Monday, February 27, 2023
Death, Overalls, Therapy, Cancer, Investigational New Drug, Maintenance, IND, FDA, RAS, Patient, Ras GTPase, Patent, KRAS, Mutation, American Cancer Society, Colorectal cancer, Non-small-cell lung cancer, NSCLC, File, Small RNA, Neoplasm, Prevalence, RNA, Nanoparticle, Pharmaceutical industry, Vaccine

Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company developing RNA-based therapeutics that address important unmet medical needs, today announced that it has filed a provisional patent application with the United States Patent and Trade Office (USPTO) to provide broad coverage of different KRAS mutations in human cancer treatment with nanoparticles comprising the Company’s OligoPhore™ platform and a single siRNA sequence.

Key Points: 
  • Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company developing RNA-based therapeutics that address important unmet medical needs, today announced that it has filed a provisional patent application with the United States Patent and Trade Office (USPTO) to provide broad coverage of different KRAS mutations in human cancer treatment with nanoparticles comprising the Company’s OligoPhore™ platform and a single siRNA sequence.
  • The new filing is intended to expand Altamira’s intellectual property related to its AM-401 development program for the treatment of KRAS-driven cancers.
  • Through mutations, the RAS proteins can be rendered persistently active, causing cancer cells to proliferate and spread in the body.
  • There exist more than a dozen different KRAS mutations, but the prevalence of mutation is exceedingly variable among different types of cancers.

Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration

Retrieved on: 
Wednesday, December 7, 2022
Collaboration, NSCLC, Security (finance), RAS, SHP2, Revolution, Ras GTPase, Research, COVID-19, Patient, GAAP, Pharmaceutical industry, Sanofi

Following termination, Revolution Medicines will regain all global rights granted to Sanofi under the agreement, including decision-making regarding research and development, and rights to all commercial proceeds from RMC-4630, a SHP2 inhibitor drug candidate in development for the treatment of patients with certain RAS-addicted cancers.

Key Points: 
  • Following termination, Revolution Medicines will regain all global rights granted to Sanofi under the agreement, including decision-making regarding research and development, and rights to all commercial proceeds from RMC-4630, a SHP2 inhibitor drug candidate in development for the treatment of patients with certain RAS-addicted cancers.
  • The companies plan to collaborate to transition all Sanofi’s rights and obligations related to RMC-4630 back to Revolution Medicines over the first half of 2023.
  • During the transition, Revolution Medicines expects that Sanofi will continue to fulfill any obligations under the Collaboration Agreement, including reimbursing Revolution Medicines’ costs, as contemplated by the Collaboration Agreement.
  • With current cash, cash equivalents and marketable securities, Revolution Medicines continues to project it can fund planned operations through 2024.

Revolution Medicines to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Nasdaq, RAS, SHP2, Webcast, Ras GTPase, Conference, Pharmaceutical industry

REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences.
  • Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured speaker in fireside chats at the H.C. Wainwright3rd Annual Precision Oncology Virtual Conference and the 5th Annual Evercore ISI HealthCONx Conference.
  • Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers.
  • Additional RAS(ON) Inhibitors in the companys pipeline include RMC-9805 (KRASG12D), currently in IND-enabling development, RMC-8839 (KRASG13C), and additional compounds targeting other RAS variants.

Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress

Retrieved on: 
Monday, November 7, 2022
Partnership, Research, Colorectal cancer, Exercise, PD-1, Revolution, Conference, Security (finance), Merck & Co., Forward-looking statement, Pancreatic cancer, Mouse Models of Human Cancer database, Amgen, Attention deficit hyperactivity disorder predominantly inattentive, Helmy Eltoukhy, Drug discovery, U.S. Securities and Exchange Commission, Ras GTPase, CRC, Neoplasm, GAAP, Patient, COVID-19, Mutation, Mirati, Nasdaq, Merck, Webcast, Cancer, SHP2, Terminology, Growth, Phosphorylation, GLOBE, Private Securities Litigation Reform Act, Large-cell lung carcinoma, Lung cancer, D, Pembrolizumab, Merck Sharp & Dohme Federal Credit Union, Pharmaceutical industry, Air cargo, NSCLC, Sanofi

REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended September 30, 2022, and provided an update on corporate progress.

Key Points: 
  • In August 2022, Amgen reported preliminary results from this trial at the IASLC 2022 World Conference on Lung Cancer.
  • During the quarter ended September 30, 2022, the company recorded a non-cash GAAP accounting adjustment that reduced collaboration revenue by $4.6 million.
  • Revolution Medicines will host a webcast this afternoon, November 7, 2022, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
  • Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events.

Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022

Retrieved on: 
Tuesday, November 1, 2022
RAS, GLOBE, SHP2, Nasdaq, Ras GTPase, Revolution, Pharmaceutical industry

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2022 on Monday, November 7, 2022, after market close.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2022 on Monday, November 7, 2022, after market close.
  • At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
  • Following the live webcast, a replay will be available on the companys website for at least 14 days.
  • Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers.

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

Retrieved on: 
Thursday, September 22, 2022
SHP2, Safety, COVID-19, RAS, U.S. Securities and Exchange Commission, Forward-looking statement, Patient, Clinical trial, Terminology, Ras GTPase, Nasdaq, Private Securities Litigation Reform Act, Collection, Research, Security (finance), GLOBE, Mutation, Cancer, Pharmaceutical industry

REDWOOD CITY, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-6291, an oral, selective, covalent KRASG12C(ON) Inhibitor designed to treat patients with cancers driven by the KRASG12C mutation. RMC-6291, which exhibits a potential best-in-class preclinical profile, is the first drug candidate from the company’s pipeline of mutant-selective RAS(ON) Inhibitors to enter the clinic. Last quarter, Revolution Medicines initiated clinical development of RMC-6236, its oral RASMULTI(ON) Inhibitor designed to treat patients with cancers driven by a variety of RAS mutations.

Key Points: 
  • RMC-6291, which exhibits a potential best-in-class preclinical profile, is the first drug candidate from the companys pipeline of mutant-selective RAS(ON) Inhibitors to enter the clinic.
  • Last quarter, Revolution Medicines initiated clinical development of RMC-6236, its oral RASMULTI(ON) Inhibitor designed to treat patients with cancers driven by a variety of RAS mutations.
  • The Phase 1/1b trial ( NCT05462717 ) sponsored by Revolution Medicines is a multicenter, open-label, dose-escalation and dose-expansion study of RMC-6291 in patients with advanced solid tumors harboring the KRASG12C mutation.
  • The primary objectives of the study are to evaluate safety and tolerability and to inform the recommended Phase 2 dose and schedule (RP2DS) for the compound.

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

Retrieved on: 
Thursday, September 1, 2022
Security (finance), COVID-19, Onyx Pharmaceuticals, Strategic planning, Research, Myers, PricewaterhouseCoopers, McKinsey & Company, Forward-looking statement, Wilson Sonsini Goodrich & Rosati, U.S. Securities and Exchange Commission, Yahoo!, GLOBE, Assertio Therapeutics, Leadership, Nasdaq, Privacy, Compliance, Revolution, Biotechnology, SHP2, RAS, Terminology, Intellectual property, Amgen, Novellus Systems, Private Securities Litigation Reform Act, Ras GTPase, Helmy Eltoukhy, Drug development, Acquisition, Contract, Management, Pharmaceutical industry

REDWOOD CITY, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced two senior management promotions, as well as the addition of a new member to its leadership team. Jack Anders, who previously served as the company’s senior vice president, finance and principal financial and accounting officer, has been promoted to chief financial officer, and Jeff Cislini, formerly vice president, deputy general counsel, has been promoted to senior vice president, general counsel and corporate secretary. Additionally, Daniel Simon will join the company as chief business officer in early September.

Key Points: 
  • He joined Revolution Medicines in 2020 as its deputy general counsel and has served as the companys senior legal advisor during his tenure.
  • Mr. Simon joins Revolution Medicines from Guardant Health where he most recently served as the companys senior vice president, biopharma business development.
  • The promotions of Jack and Jeff are well-deserved and speak to the important contributions that they have each made to the success of Revolution Medicines as members of the management team.
  • We are also excited to welcome Daniel to the Revolution Medicines team as the companys first chief business officer.